60. 再生不良性貧血 [臨床試験数:218,薬物数:362(DrugBank:81),標的遺伝子数:39,標的パスウェイ数:155

Searched query = "Aplastic anemia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
9 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02162420January 201510/6/2014Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic AnemiaHematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic AnemiaDyskeratosis Congenita;Aplastic AnemiaDrug: Alemtuzumab;Drug: Fludarabine;Drug: Cyclophosphamide;Radiation: Total Body Irradiation;Biological: Stem Cell Transplant;Drug: Anti-thymocyte globulinMasonic Cancer Center, University of MinnesotaNULLRecruitingN/A70 YearsAll50N/AUnited States
2NCT01659606July 20126/8/2012Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis CongenitaRadiation- and Alkylator-free Hematopoietic Cell Transplantation for Bone Marrow Failure Due to Dyskeratosis Congenita / Telomere DiseaseDyskeratosis Congenita;Hoyeraal Hreidarsson Syndrome;Revesz Syndrome;Aplastic AnemiaBiological: alemtuzumab;Drug: Fludarabine;Drug: Cyclosporins;Drug: Mycophenolate mofetilBoston Children's HospitalDana-Farber Cancer Institute;Children's Hospital Medical Center, Cincinnati;Children's Hospital Los Angeles;Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;Baylor College of Medicine;Children's Hospital of Philadelphia;Memorial Sloan Kettering Cancer Center;University of Wisconsin, Madison;Karolinska University Hospital;Hackensack Meridian Health;Duke University;Oslo University Hospital;Children's Mercy Hospital Kansas CityRecruitingN/A65 YearsAll40Phase 2United States;Norway;Sweden
3NCT01408342July 201129/7/2011Alemtuzumab and Rituximab in Aplastic AnemiaLow-doses Alemtuzumab and Rituximab Combination as First Line Treatment in Aplastic AnemiaAplastic AnemiaDrug: Alemtuzumab and RituximabHospital Universitario Dr. Jose E. GonzalezNULLWithdrawn12 MonthsN/ABoth0N/AMexico
4NCT01191749August 201027/8/2010Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)Phase II Pilot Study Of Alemtuzumab In Patients With Low Or INT-1 Risk Myelodysplastic Syndrome (MDS), Aplastic Anemia (AA), Or T-Cell Large Granular Lymphocytic Leukemia (T-LGL)LeukemiaDrug: AlemtuzumabM.D. Anderson Cancer CenterNULLTerminatedN/AN/AAll7Phase 2United States
5EUCTR2008-001151-22-IT06/06/200714/06/2011ALEMTUZUMAB AND LOW-DOSE CYCLOSPORINE-A AS ALTERNATIVE IMMUNOSUPPRESSIVE TREATMENT FOR SEVERE APLASTIC ANEMIA (SAA) AND SINGLE-LINEAGE APLASTIC PATIENTS. - AlesaaALEMTUZUMAB AND LOW-DOSE CYCLOSPORINE-A AS ALTERNATIVE IMMUNOSUPPRESSIVE TREATMENT FOR SEVERE APLASTIC ANEMIA (SAA) AND SINGLE-LINEAGE APLASTIC PATIENTS. - Alesaa Aplastic anemia and single-lineage bone marrow failure
MedDRA version: 13.1Level: PTClassification code 10002965Term: Aplasia pure red cellSystem Organ Class: 10005329 - Blood and lymphatic system disorders
MedDRA version: 13.1Level: LLTClassification code 10047350Term: Very few granulocyte precursorsSystem Organ Class: 10005329 - Blood and lymphatic system disorders
MedDRA version: 13.1Level: PTClassification code 10002967Term: Aplastic anaemiaSystem Organ Class: 10005329 - Blood and lymphatic system disorders
MedDRA version: 13.1Level: PTClassification code 10001507Term: AgranulocytosisSystem Organ Class: 10005329 - Blood and lymphatic system disorders
Trade Name: MABCAMPATH
INN or Proposed INN: Alemtuzumab
UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO IINULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
50Italy
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00895739June 20067/5/2009Alemtuzumab and Low-Dose Cyclosporine in Treating Patients With Severe Aplastic Anemia or Acquired Marrow FailureAlemtuzumab and Low-Dose Cyclosporine-A as Alternative Immunosuppressive Treatment for Severe Aplastic Anemia (SAA) and Single-Lineage Aplastic PatientsNonmalignant NeoplasmBiological: alemtuzumab;Drug: cyclosporineFederico II UniversityNULLRecruiting18 YearsN/ABoth50Phase 2Italy
7NCT00260689November 28, 20051/12/2005Three Immunosuppressive Treatment Regimens for Severe Aplastic AnemiaA Randomized Study of Three Immunosuppressive Regimens in Treatment Naive Patients With Severe Aplastic Anemia: Horse ATG/CsA Taper vs Rabbit-ATG/CsA vs AlemtuzumabImmunosuppresion;Thrombocytopenia;Pancytopenia;NeutropeniaBiological: Anti-thymocyte globulin (rabbit);Biological: Anti-thymocyte globulin (horse);Drug: Cyclosporine;Drug: AlemtuzumabNational Heart, Lung, and Blood Institute (NHLBI)NULLCompleted2 YearsN/AAll136Phase 2United States
8NCT00195624September 15, 200516/9/2005Alemtuzumab to Treat Severe Aplastic AnemiaA Pilot Study of Alemtuzumab (Campath) in Patients With Relapsed or Refractory Severe Aplastic AnemiaSevere Aplastic Anemia, Refractory;Severe Aplastic Anemia, RelapseBiological: Alemtuzumab (Campath );Drug: CyclosporineNational Heart, Lung, and Blood Institute (NHLBI)NULLCompleted2 Years110 YearsAll47Phase 2United States
9JPRN-C0000003562004/12/0120/03/2006Evaluation of the safety and efficacy of allogeneic hematopoietic stem cell transplantation (HSCT) using alemtuzumab for patients with aplastic anemia Aplastic anemiaAlemtuzumab is added to the fludarabine-based regimen at 0.16 – 0.25 mg/kg per day for 6 days (days -10 to -5).GCP-ISS HE0403 groupNULLComplete: follow-up complete20years-old65years-oldMale and Female38Phase 1,2Japan